Just before the 23andMe SPAC deal closed, the stock belonging to its merger ... giving investors the impression it is a ...

Me collected information from survey questions about personal health and beyond, such as drinking habits and risk tolerance.

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data ...

The direct-to-consumer DNA testing service 23andMe filed for bankruptcy earlier this month, putting millions of customers' ...

Me is pursuing a sale after filing for bankruptcy, leading many customers to look into deleting their data from the company.

raised concerns with Treasury Secretary Scott Bessent and 23andMe executives over the risk that Chinese companies ... Treasury’s Committee on Foreign Investment in the United States, a panel ...

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations. When companies opt ...

GlaxoSmithKline also made a $300 million equity investment in 23andMe. When 23andMe went public ... if it shows that they have or are at high risk of developing a genetic disease or disorder.

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...